Source: Fox News
Summary
A study published in Nature Metabolism suggests that glucosamine, a popular supplement for joint health, may be linked to faster progression from mild cognitive impairment to Alzheimer’s disease. Researchers from the University of Florida analyzed medical records, mouse models, and human brain tissue. They found that glucosamine increased sugar chains on proteins in Alzheimer’s-affected brains, potentially disrupting nerve cell communication. Among patients with mild cognitive impairment, glucosamine users had a 25% higher risk of progressing to dementia. The study did not prove causation and called for further research.
Our Reading
This guidance has been heard before.
Glucosamine, once seen as a safe joint aid, now appears to have a new risk.
Studies show it may worsen dementia in vulnerable brains.
But the research is observational, not conclusive.
Old advice, new warnings — the same supplement, different context.
Author: Evan Null
Glucosamine and Cognitive Health
Many older adults take glucosamine to help with joint pain. It is a natural compound found in cartilage. People often use it as a supplement for aging joints. The study looked at how glucosamine affects the brain. It found a possible link between the supplement and faster progression to Alzheimer’s disease.
Research Findings
The study analyzed medical records of people with mild cognitive impairment. It also looked at mouse models and human brain tissue. Researchers found that glucosamine increased sugar chains on proteins in Alzheimer’s brains. These sugar chains may interfere with nerve cell communication. The study did not prove that glucosamine causes Alzheimer’s.
Study Limitations
The research relied on medical records, which may not capture all supplement use. It did not track exact doses or how often people took the supplement. The study also did not examine people with healthy brains. Researchers called for more controlled studies to confirm the findings.
Expert Opinions
Experts say the results should be treated as a safety signal. They do not recommend glucosamine for slowing Alzheimer’s. More research is needed to understand the relationship. Some experts suggest that people with cognitive impairment or dementia should talk to their doctors before taking the supplement.
Future Research
The next step is a well-designed clinical trial. It will look at how glucosamine affects cognitive decline in people with dementia. Researchers say the evidence is not strong enough to make recommendations. They emphasize the need for proper studies to determine the supplement’s effects on the brain.
